Reaktionsgleichung
C[CH:2]([N:12]1[CH2:17][CH2:16][CH:15]([CH2:18][C:19]2[CH:20]=[CH:21][CH:22]=CC=2)CC1)[CH:3](O)[C:4]1[CH:5]=[CH:6][C:7]([OH:10])=[CH:8][CH:9]=1.C(O)(C(O)=O)C(O)[C:27](O)=[O:28].CN1[C@@H]2C[C@@H:42]([O:44]C(C(C3C=CC=CC=3)CO)=O)C[C@H]1CC2.[CH3:56][O:57]C([C@@H]1[C@H]2C[C@@H]3N(C[C@@H]2CC[C@@H]1O)CCC1C2C=CC=CC=2NC3=1)=O.[CH2:82]1CCN(C2C3N=C(N(CCO)CCO)N=C(N4CCCCC4)C=3N=C(N(CCO)CCO)N=2)CC1.C1C=NC(N2CCN(CC3C=CC4OCOC=4C=3)CC2)=NC=1>>[CH3:27][O:28][C:20]1[CH:21]=[CH:22][C:15]([CH2:16][C:17]2[N:12]=[CH:2][CH:3]=[C:4]3[C:9]=2[CH:8]=[C:7]([O:10][CH3:82])[C:6]([O:57][CH3:56])=[CH:5]3)=[CH:18][C:19]=1[O:44][CH3:42]Komponenten
6
Versuchsvorschrift
ifenprodil tartrate approximately 0.75 mg as an alpha1 blocker; atropine approximately 0.025 mg as an anticholinergic; yohimbine approximately 0.075 mg as an alpha2 blocker; dipyridamol approximately 0.25 mg as a phosphodiasterase inhibitor; piribedil approximately 0.225 mg as a dopaminergic; and alprostil approximately 33 μg as a prostaglandin.
Quellen und Nachweise
- ORD-Eintrag
- ord-9a9b9e7ea289493c8c96112a591cb49f
- Quelldatensatz
- uspto-grants-1992_09
- Patentnummer
- US05145852
Verknüpfte Notizen
Wird geladen…